Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I Milano

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 3226-3235

  Cimmino, Giovanni ^a   Ibanez, Borja ^a,c   Vilahur, Gemma ^b   Speidl, Walter S ^a   Fuster, Valentin ^a   Badimon, Lina ^b   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CSIC   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

ApoA I; Atherosclerosis; Inflammation; Lipoproteins; Reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN A1; CD36 ANTIGEN; CHOLESTEROL; INDUCIBLE NITRIC OXIDE SYNTHASE;

ANIMAL; AORTA; ARTICLE; ATHEROSCLEROSIS; CYTOLOGY; FOAM CELL; INFLAMMATION; LIPID PEROXIDATION; LIVER; MALE; METABOLISM; MOUSE; RABBIT; TRANSPORT AT THE CELLULAR LEVEL; UPREGULATION;

ANIMALS; ANTIGENS, CD36; AORTA; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL; FOAM CELLS; INFLAMMATION; LIPID PEROXIDATION; LIVER; MALE; MICE; NITRIC OXIDE SYNTHASE TYPE II; RABBITS; UP-REGULATION;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 77449085122     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00614.x     Document Type: Article

References (33)

1. Ibanez B, Vilahur G, Badimon J. Plaque progression and regression in atherothrombosis. J Thromb Haemost. 2007, 5:292-9.
2. Viles-Gonzalez JF, Fuster V, Corti R. Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. Curr Opin Cardiol. 2003, 18:286-94.
3. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990, 85:1234-41.
4. Badimon JJ, Badimon L, Galvez A. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest. 1989, 60:455-61.
5. Franceschini G, Sirtori CR, Capurso A. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980, 66:892-900.
6. Ameli S, Hultgardh-Nilsson A, Cercek B. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994, 90:1935-41.
7. Shah PK, Nilsson J, Kaul S. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 1998, 97:780-5.
8. Kaul S, Coin B, Hedayiti A. Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. J Am Coll Cardiol. 2004, 44:1311-9.
9. Nissen SE, Tsunoda T, Tuzcu EM. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Jama. 2003, 290:2292-300.
10. Ibanez B, Vilahur G, Cimmino G. Rapid change in plaque size, composition and molecular footprint following recombinant ApoA-IMilano (ETC-216) administration. Magnetic Resonance Imaging Study in an Experimental Model of Atherosclerosis. J Am Coll Cardiol. 2008, 51:1104-9.
11. Corti R, Osende J, Hutter R. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis. 2007, 190:106-13.
12. Corti R, Osende JI, Fallon JT. The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J Am Coll Cardiol. 2004, 43:464-73.
13. Helft G, Worthley SG, Fuster V. Atherosclerotic aortic component quantification by noninvasive magnetic resonance imaging: an in vivo study in rabbits. J Am Coll Cardiol. 2001, 37:1149-54.
14. Yagi K. Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol Biol. 1998, 108:101-6.
15. Dawn-Linsley M, Ekinci FJ, Ortiz D. Monitoring thiobarbituric acid-reactive substances (TBARs) as an assay for oxidative damage in neuronal cultures and central nervous system. J Neurosci Methods. 2005, 141:219-22.
16. Frolich JC. Measurement of icosanoids. Report of the Group for Standardization of Methods in Icosanoid Research. Prostaglandins. 1984, 27:349-68.
17. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957, 226:497-509.
18. Miller JP, Mao SJ, Patsch JR. The measurement of apolipoprotein A-I in human plasma by electroimmunoassay. J Lipid Res. 1980, 21:775-80.
19. Badimon JJ, Kottke BA, Chen TC. Quantification and immunolocalization of apolipoprotein E in experimental atherosclerosis. Atherosclerosis. 1986, 61:57-66.
20. Wang L, Sharifi BG, Pan T. Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J Am Coll Cardiol. 2006, 48:1459-68.
21. Parolini C, Marchesi M, Lorenzon P. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-Imilano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol. 2008, 11:1098-103.
22. Timmins JM, Lee JY, Boudyguina E. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest. 2005, 115:1333-42.
23. Eriksson M, Carlson LA, Miettinen TA. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 1999, 100:594-8.
24. Yancey PG, de la Llera-Moya M, Swarnakar S. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem. 2000, 275:36596-604.
25. Wang X, Collins HL, Ranalletta M. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007, 117:2216-24.
26. Weibel GL, Alexander ET, Joshi MR. Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. Arterioscler Thromb Vasc Biol. 2007, 27:2022-9.
27. Lebherz C, Sanmiguel J, Wilson JM. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol 2007, 6:15.
28. Franceschini G, Calabresi L, Chiesa G. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol. 1999, 19:1257-62.
29. Favari E, Gomaraschi M, Zanotti I. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux. J Biol Chem. 2007, 282:5125-32.
30. McAdam BF, Catella-Lawson F, Mardini IA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999, 96:272-7.
31. Miyoshi T, Li Y, Shih DM. Deficiency of inducible NO synthase reduces advanced but not early atherosclerosis in apolipoprotein E-deficient mice. Life Sci. 2006, 79:525-31.
32. Hutter R, Valdiviezo C, Sauter BV. Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. Circulation. 2004, 109:2001-8.
33. Chiesa G, Monteggia E, Marchesi M. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res. 2002, 90:974-80.